Company announcement - Announcements and Circulars - Investor - XZenith Biopharm

Investor relations

Company announcement Performance presentation

Performance promotion

Company announcement

All

INSIDE INFORMATION NOTIFICATION LETTER OF THE CSRC REGARDING THE APPLICATION FOR THE PROPOSED IMPLEMENTATION OF H SHARE FULL CIRCULATION
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 March 2026
VOLUNTARY ANNOUNCEMENT - LICENSING AND SUPPLY AGREEMENT WITH BOSTON ONCOLOGY FOR BIREOCICLIB AND DIROZALKIB
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025
VOLUNTARY ANNOUNCEMENT FINAL ANALYSIS RESULTS OF THE PHASE 3 CLINICAL STUDY (BRIGHT-2) OF BIREOCICLIB IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF HR+/HER2- ADVANCED BREAST CANCER PUBLISHED IN TOP-TIER INTERNATIONAL JOURNAL JAMA ONCOLOGY
VOLUNTARY ANNOUNCEMENT COMPLETION OF ENROLLMENT OF ALL SUBJECTS IN PHASE III CLINICAL TRIAL IN CHINA OF ANAPRAZOLE SODIUM ENTERIC-COATED TABLETS (AN JIU WEI) FOR THE TREATMENT OF REFLUX ESOPHAGITIS
DATE OF BOARD MEETING
VOLUNTARY ANNOUNCEMENT INCLUSION OF THE SHARES OF THE COMPANY IN STOCK LIST OF HONG KONG STOCK CONNECT
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 28 February 2026
VOLUNTARY ANNOUNCEMENT MARKETING APPROVAL FOR THE THIRD INDICATION OF XUANYUENING (BIREOCICLIB TABLETS) FOR THE FIRST-LINE TREATMENT OF HR+/HER2- ADVANCED BREAST CANCER GRANTED BY THE NMPA

<1 2 3 4 5 6 7 8 >